Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Blevins

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Postgraduate Medicine|May 14, 2010
Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetesThomas Blevins, Jenny Han, Dawn Nicewarner, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|April 24, 2023
Breaking Barriers With Basal Insulin Biosimilars in Type 2 DiabetesSimon Heller, João Filipe Raposo, Santiago Tofé, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 1, 2022
Expert Roundtable on Continuous Glucose MonitoringCheryl Rosenfeld, Thomas Blevins, Grazia Aleppo, et al.
The Journal of Clinical Endocrinology and Metabolism|February 11, 2011
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetesThomas Blevins, John Pullman, Jaret Malloy, et al.
Diabetes Care|June 1, 2014
Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)Carol Wysham, Thomas Blevins, Richard Arakaki, et al.
Diabetes Care|June 25, 2015
Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159-2167Carol Wysham, Thomas Blevins, Richard Arakaki, et al.
Journal of Diabetes Science and Technology|November 11, 2025
Replacing or Supplementing Automated Insulin Delivery With Inhaled Insulin: A 90-Day Randomized Controlled TrialKevin B Kaiserman, Johanna Ulloa, Jennifer Pleitez, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|October 21, 2024
Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 DiabetesRoy W Beck, Carol J Levy, Yogish C Kudva, et al.
Diabetes Technology & Therapeutics|July 8, 2020
Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID StudyThomas Blevins, Wendy Lane, David Rodbard, et al.
Journal of Diabetes|April 17, 2014
Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspartWilliam V Tamborlane, Eric Renard, R Paul Wadwa, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Postgraduate Medicine|May 14, 2010
Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetesThomas Blevins, Jenny Han, Dawn Nicewarner, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|April 24, 2023
Breaking Barriers With Basal Insulin Biosimilars in Type 2 DiabetesSimon Heller, João Filipe Raposo, Santiago Tofé, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 1, 2022
Expert Roundtable on Continuous Glucose MonitoringCheryl Rosenfeld, Thomas Blevins, Grazia Aleppo, et al.
The Journal of Clinical Endocrinology and Metabolism|February 11, 2011
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetesThomas Blevins, John Pullman, Jaret Malloy, et al.
Diabetes Care|June 1, 2014
Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)Carol Wysham, Thomas Blevins, Richard Arakaki, et al.
Diabetes Care|June 25, 2015
Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159-2167Carol Wysham, Thomas Blevins, Richard Arakaki, et al.
Journal of Diabetes Science and Technology|November 11, 2025
Replacing or Supplementing Automated Insulin Delivery With Inhaled Insulin: A 90-Day Randomized Controlled TrialKevin B Kaiserman, Johanna Ulloa, Jennifer Pleitez, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|October 21, 2024
Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 DiabetesRoy W Beck, Carol J Levy, Yogish C Kudva, et al.
Diabetes Technology & Therapeutics|July 8, 2020
Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID StudyThomas Blevins, Wendy Lane, David Rodbard, et al.
Journal of Diabetes|April 17, 2014
Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspartWilliam V Tamborlane, Eric Renard, R Paul Wadwa, et al.
Pageof 4